Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis

Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis

Serum neurofilament light chain (sNfL) levels have been proposed as a biomarker of the clinical activity, disability progression, and response to treatment of people with multiple sclerosis (PwMS); however, questions remain about its implementation in clinical practice. Ocrelizumab (OCR) has proven...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine Vol. 14; no. 7; p. 692
Main Authors: Barrero Hernández, Francisco J, Romero Villarrubia, Ana, Muñoz Fernández, Carmen, Guillén Martinez, Virginia, Aguilera Del Moral, Almudena, Barrios-López, José María, Ramírez Rivas, Maria A, Gálvez Muñoz, Antonio J, Piñar Morales, Raquel
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 27-06-2024
Subjects:
Age
Biomarkers
Body mass index
Brain research
Clinical outcomes
Clinical trials
Disease
Hospitals
Light
Magnetic resonance imaging
Multiple sclerosis
Neurodegeneration
Standard scores
United States > US
Spain
ocrelizumab
real world
neurofilament
no evidence of disease activity
multiple sclerosis
disease-modifying treatment
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Serum neurofilament light chain (sNfL) levels have been proposed as a biomarker of the clinical activity, disability progression, and response to treatment of people with multiple sclerosis (PwMS); however, questions remain about its implementation in clinical practice. Ocrelizumab (OCR) has proven effective in improving clinical and radiological outcomes and reducing sNfL levels. This real-life study followed the sNfL levels of 30 PwMS treated for 12 months with OCR and evaluated the usefulness of this biomarker for their short-term prognosis, considering expanded disability status scale (EDSS), annualized relapse rate (ARR), radiological activity, and NEDA-3 values. OCR reduced ARR in 83% of PwMS and radiological activity in 80%. EDSS was maintained, while NEDA-3 was achieved in 70% at 12 months. OCR produced an early reduction in sNfL levels (at 3 months). At baseline, greater MRI-evaluated radiological activity was associated with higher sNfL levels. sNfL levels over the first 12 months of treatment did not predict a suboptimal response or sustained control of the disease. Longer-term studies are needed to explore the predictive usefulness of sNfL levels in PwMS treated with high-efficacy drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm14070692